1028 Ex vivo chemotherapy resistance of metabolically reprogrammed autologous Th1/Tc1 cells (RAPA-201): Towards the clinical translation of immune-sparing host conditioning
Main Authors: | Martin Gutierrez, Deborah Glass, Jee Hyun Park, Tania Felizardo, Daniel H Fowler |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning
by: Lawrence G Lum, et al.
Published: (2023-11-01) -
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma
by: Lawrence G Lum, et al.
Published: (2025-01-01) -
Autologous, lentivirus‐modified, T‐rapa cell “micropharmacies” for lysosomal storage disorders
by: Murtaza S Nagree, et al.
Published: (2022-03-01) -
Combinations of Single-Gene Biomarkers Can Precisely Stratify 1,028 Adult Gliomas for Prognostication
by: Aden Ka-Yin Chan, et al.
Published: (2022-04-01) -
1028 nm single mode Ytterbium-doped fiber laser
by: Paul, Mukul Chandra, et al.
Published: (2009)